Renal Toxicity After Radionuclide Therapy
Journal Title: Nuclear Medicine Seminars - Year 2019, Vol 5, Issue 3
Abstract
With the introduction of radionuclide therapies, the probability of toxicity has increased in critical organs such as kidney and bone marrow. Although these toxicity rates are relatively low in targeted therapies such as radionuclide therapy, a number of organs, especially the kidneys, are affected by radiation. Radionuclide therapies that led to the major risk for renal toxicity are neuroendocrine tumor treatment with beta-emitting radioisotopes (Lu-177 and Y-90) labeled with [DOTA0, Tyr3]-octreotate (DOTATATE), and prostate cancer treatment with alpha or beta emitters, such as Lu-177 or Ac-225, labeled with prostate specific membrane antigen. The intense uptake and prolonged retention of these radioactive molecules in the kidneys raise concerns about the potential toxicity of kidneys by radiation that puts therapeutic efficacy at risk. In this review, nephrotoxicity resulting from radionuclide therapy, particularly Lu-177 and Y-90, and therapeutic options to reduce the toxicity are discussed.
Authors and Affiliations
Nalan Alan Selçuk, Türkay Toklu
Keywords
Related Articles
- EP ID EP685341
- DOI 10.4274/nts.galenos.2019.0029
- Views 152
- Downloads 0
A Guide to Current Good Radiopharmacy Practices in Radiopharmaceutical Preparation (PET, THERAPY, SPECT)
Radiopharmaceutical products are inorganic compounds, organic compounds, peptides, proteins, monoclonal antibodies and fragments, and oligonucleotides labeled with radionuclides whose half-life ranges from a few minutes...
Procedur Guideline for Lymphoscintigraphy and Sentinel Lymph Node in Breast Cancer
Sentinel lymph node (SLN) detection by lymphoscintigraphy (LS) and using intraoperative gamma probe is the mostly important prognostic factor in patients with breast cancer. Sentinel lymph node biopsy (SLNB) is a procedu...
Practical Guidance on Peptide Receptor Radionuclide Therapy
Peptide receptor radionuclide therapy (PRRT) have been successfully used for the past 20 years to target metastatic or inoperable neuroendocrine tumors expressing the somatostatin receptors. Both prospective and retrospe...
Procedur Guideline for Prostate Cancer Imaging: Ga68 PSMA PET/CT
This guideline, mainly for nuclear medicine physicians contains recommendations in terms of procedure, reporting and interpretation in order to standardize Gallium-68 prostate specific membrane antigen (Ga-68 PSMA) posit...
Procedure Guideline for Detection of Inflammation with F-18 FDG PET/CT in Cardiac Sarcoidosis
Histologic confirmation of cardiac sarcoidosis (CS) is challenging. When taken into account of either the invasive nature or potential false negativity of the endomyocardial biopsy, imaging methods represent as a major a...